ClinicalTrials.gg
CompletedNCT01690299Updated Mar 15, 2022Results posted

Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

A Phase 3 interventional study of Apremilast and Etanercept in Psoriasis and Psoriatic Arthritis, sponsored by Amgen. Completed at 82 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-15.

Primary conditionArthritis, PsoriaticRegistry: PsoriasisReclassifiedWhy we changed it
Registry
Psoriasis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Arthritis, Psoriatic
Why
  1. The study's listed conditions name Arthritis, Psoriatic, a narrower term within Psoriasis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing apremilast in Arthritis, Psoriatic — 3 open to participants now, 3 under way, 1 of them phase 3. apremilast · Arthritis, Psoriatic.

Enrollment
8th of 17
250 · median 219
Started
2012
the only one that year
Phase 3
8 of 17
1 open now
Registered
6th of 17
by date
Lead sponsor
11 of 17
Amgen

Among the 17 studies testing apremilast in Arthritis, Psoriatic, this one is the 8th largest by enrollment, is the only one that started in 2012, is one of 8 in phase 3, and was the 6th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

3 of the 17 studies testing apremilast in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About apremilast

apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing apremilast in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

This study will test the clinical effectiveness and safety of apremilast compared with placebo as well as etanercept compared with placebo in the same group of patients with moderate to severe plaque psoriasis.

Read the detailed description

This is a phase 3b, multicenter, randomized, placebo-controlled, double-blind, double-dummy, study of the efficacy and safety of apremilast, etanercept, and placebo, in adults with moderate to severe plaque psoriasis.

250 participants will be randomized 1:1:1 to the three treatment groups. All subjects will receive both tablets and injections through Week 16.

The study will consist of four phases:

  • Screening Phase - up to 35 days
  • Double-blind Placebo-controlled Phase - Weeks 0-16
  • Apremilast Extension Phase - Weeks 16-104
  • Post-treatment Observational Follow-up Phase

During the double-blind, placebo-controlled phase, subjects will receive treatment with one of the following:

  • apremilast (APR) 30 mg tablets orally twice a day (BID) plus once weekly (QW) evaluator/subject-blinded subcutaneous (SC) saline (placebo) injections (1 mL x 2 injections SC), or
  • etanercept (ETN) 50 mg evaluator/subject-blinded subcutaneous (SC) once weekly (QW) injections (2 x 25 mg) plus placebo tablets orally twice a day (BID), or
  • placebo tablets and evaluator/subject-blinded subcutaneous (SC) saline (placebo) injections.

All subjects will be asked to participate in a 4-week Post-treatment Observational Follow-up Phase either upon completion of the study or upon discontinuation of investigational product for those subjects who terminate the study early.

03

Conditions studied

  • Psoriasis
  • Psoriatic Arthritis

Browse trials for

Keywords

  • Psoriasis
  • arthritis
  • psoriatic
  • palmoplantar
  • scalp
  • psoriasis pill
  • psoriasis tablet
  • plaque psoriasis
  • plaque type psoriasis
  • moderate to severe plaque type psoriasis
  • psoriatic arthritis
04

In context

Arthritis, Psoriatic Reclassified

601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.

This study's enrollment of 250 is above the median of 145 across 336 interventional studies indexed under Arthritis, Psoriatic.

Browse Arthritis, Psoriatic studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Compared within Arthritis, Psoriatic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Psoriasis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females, ≥ 18 years of age
  • Diagnosis of chronic, moderate to severe plaque psoriasis for at least 12 months prior to Screening, and a candidate for phototherapy and/or systemic (including etanercept) therapy
  • Had an inadequate response, intolerance, or to at least 1 conventional systemic agent for the treatment of psoriasis.
  • No prior exposure to biologics for treatment of psoriatic arthritis or psoriasis

Exclusion criteria

Exclusion Criteria:

  • Other than psoriasis, history of any and uncontrolled systemic diseases; any condition, including the presence of laboratory abnormalities, which would place the subject at unacceptable risk if he/she were to participate in the study.
  • Pregnant or breast feeding.
  • Have failed more than 3 systemic agents for treatment of psoriasis.
  • History of allergy to any component of the product (IP), including human immunoglobulin (Ig) proteins or allergy to etanercept.
  • surface antigen or anti- antibody positive at Screening.
  • Latent, active tuberculosis (TB) or inadequately treated TB; nontuberculous mycobacterial infection or opportunistic infection (eg, cytomegalovirus, Pneumocystis carinii, aspergillosis, Clostridium difficile).
  • Have a history of, or ongoing, chronic or recurrent infectious disease
  • Have received, or are expected to receive, any live virus or bacterial vaccination within 3 months before first administration of IP, or through Week 20 during the study.
  • Had a Bacillus Calmette-Guérin (BCG) vaccination within 1 year prior to screening.
  • History of positive (HIV), or have congenital or acquired immunodeficiency (eg, common variable immunodeficiency disease).
  • Active substance abuse or a history of substance abuse within 6 months prior to Screening.
  • or history of malignancy, except for treated [ie, cured] basal cell or squamous cell in situ skin carcinomas and cervical intraepithelial neoplasia [CIN] or carcinoma in situ of the cervix with no evidence of recurrence within the previous 5 years.
  • Psoriasis flare or rebound within 4 weeks prior to Screening.
  • Topical therapy within 2 weeks of randomization or systemic therapy for psoriasis within 4 weeks prior to randomization
  • Use of phototherapy within 4 weeks prior to randomization or prolonged sun exposure or use of tanning booths or other ultraviolet (UV) light sources.
  • Any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamic half lives, if known (whichever is longer).
  • Prior treatment with apremilast or etanercept.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
250 participants (actual)

Study arms

  • Experimental
    Apremilast 30 mg plus placebo injection

    Apremilast 30 mg tablets orally twice a day (BID) plus once weekly (QW) evaluator/subject-blinded subcutaneous (SC) saline (placebo) injections

    Drug: Apremilast · Drug: Placebo injection

  • Experimental
    Etanercept 50 mg plus placebo tablet

    Etanercept 50 mg evaluator/subject-blinded SC QW injections plus placebo tablets orally BID

    Drug: Etanercept · Drug: Placebo tablet

  • Placebo comparator
    Oral placebo tablets plus SC placebo injections

    Identically matching placebo tablets and evaluator/subject-blinded SC injections

    Drug: Placebo tablet · Drug: Placebo injection

Interventions

  • Apremilast 30 mg tablet orally BID

    Also known as: CC-10004, Otezla

  • Etanercept 50 mg evaluator/subject-blinded SC QW injection

    Also known as: Enbrel

  • DrugPlacebo tablet

    Placebo tablets BID

  • DrugPlacebo injection

    Once weekly evaluator/subject-blinded SC placebo (1 mL x 2 injections SC)

07

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved a 75% Improvement (Response) in the Psoriasis Area Severity Index (PASI-75) for the Comparison Between Apremilast and Placebo at Week 16 From Baseline

    PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The PASI score was set to missing if any severity score or degree of involvement was missing.

    Time frame: Baseline to Week 16

Secondary outcomes

  1. Percentage of Participants Who Achieved a 75% Improvement (Response) in the Psoriasis Area and Severity Index (PASI) for the Comparison Between Etanercept 50mg SC QW and Placebo at Week 16

    PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The PASI score was set to missing if any severity score or degree of involvement was missing.

    Time frame: Baseline and Week 16

  2. Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of Clear (0) or Almost Clear (1) With at Least 2 Points Reduction for Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16

    The sPGA is an assessment by the Investigator of the overall disease severity at the time of evaluation. The sPGA is a 5-point scale ranging from 0 (clear) to 4 (severe), incorporating an assessment of the severity of the three primary signs of the disease: erythema, scaling and plaque elevation. When making the assessment of overall severity, the Investigator should factor in areas that have already been cleared (ie, have scores of 0) and not just evaluate remaining lesions for severity, ie, the severity of each sign is averaged across all areas of involvement, including cleared lesions. In the event of different severities across disease signs, the sign that is the predominant feature of the disease should be used to help determine the sPGA score.

    Time frame: Baseline and Week 16

  3. Percent Change From Baseline in the Affected Body Surface Area (BSA) for Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16

    BSA is a measurement of involved skin. The overall BSA affected by psoriasis was estimated based on the palm area of the participant's hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total body surface area. BSA percent change from baseline was determined at each visit of the study, and is calculated as 100\*(post-baseline BSA - baseline BSA) / baseline BSA.

    Time frame: Baseline to Week 16

  4. Percentage of Participants Who Achieved a 50% Improvement (Response) in the Psoriasis Area Severity Index (PASI-50) for Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16

    PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 16. The PASI score was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The PASI score was set to missing if any severity score or degree of involvement was missing.

    Time frame: Baseline to Week 16

  5. Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score In Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16

    DLQI is a simple, compact, and practical questionnaire for use in a dermatology clinical setting to assess limitations related to the impact of skin disease. The instrument contains ten items dealing with the participant's skin. With the exception of Item Number 7, the participant responds on a four-point scale, ranging from "Very Much" (score 3) to "Not at All" or "Not relevant" (score 0). Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No, scores 3 or 0 respectively), and if "No," then the participant is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being "A lot," "A little," or "Not at all" (scores 2, 1, or 0 respectively). The DLQI total score is derived by summing all item scores, which has a possible range of 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best.

    Time frame: Baseline to Week 16

  6. Change From Baseline in the Mental Component Summary (MCS) Score of the Medical Outcome Study Short Form 36-item (SF-36) Health Survey Version 2.0 in Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16

    The SF-36 is a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Scores from the 8 scales were transformed to the norm-based scores using weights from U.S. general population to have a mean of 50 and variance = 10, with higher scores indicating better health. From these 8 scale, two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS), both having the same mean of 50 and variance = 10 as noted for the individual scales for the U.S. general population, and with higher scores indicating better health. For MCS, change from baseline was calculated, where change = visit value - baseline value.

    Time frame: Baseline to Week 16

  7. Percentage of Participants Who Achieved a Lattice System Physician's Global Assessment (LS-PGA) Score of Clear (0) or Almost Clear at Week 16 in Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16

    The Lattice System Physician's Global Assessment is a global assessment performed by the investigator of psoriasis severity. Integrating ranges of BSA involvement with assessments of overall plaque severity (using a 4 point scale from none to marked for the signs of plaque elevation, erythema and scale), the LS-PGA produces an overall assessment of psoriasis severity on an 8-point scale, ranging from clear to very severe. To determine the final score, the lattice portion is governed by the BSA and among the plaque qualities, weights plaque elevation as most important, erythema next, and scale least.

    Time frame: Baseline to Week 16

  8. Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Placebo-Controlled Phase

    A TEAE is an AE with a start date on or after the date of the first dose of study drug and no later than 28 days after the last dose of study drug for participants who discontinued early. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen during the study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the patient's health, including laboratory test values, regardless of etiology. Any worsening (ie, clinically significant adverse change in frequency or intensity of a preexisting condition) should be considered an AE. A serious AE (SAE) is any untoward AE that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize or may require intervention to prevent one of the outcomes above.

    Time frame: Week 0 to Week 16; mean duration of exposure was 14.90 weeks for placebo group, 15.13 weeks for apremilast group and 15.87 weeks for Etanercept group

  9. Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Apremilast-exposure Period

    A TEAE in the apremilast-exposure phase is an AE with a start date on or after the date of the first dose of study drug and no later than 28 days after the last dose of study drug. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen during the study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE. A serious AE (SAE) is any untoward AE that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize or may require intervention to prevent one of the outcomes listed above.

    Time frame: From the first dose of apremilast (either Week 0 for participants originally randomized to apremilast or Week 16 for those originally randomized to placebo or etanercept who were switched to apremilast at week 16) until 28 days after last apremilast dose

  10. Psoriasis Flare/Rebound

    Psoriasis flare is an AE and represents an atypical or unusual worsening of disease during treatment. It is defined as a sudden intensification of psoriasis requiring medical intervention or a diagnosis of new generalized erythrodermic, inflammatory, or pustular psoriasis. Rebound is an AE and is defined as a severe and sudden worsening of disease that occurs after treatment has been discontinued. This exacerbation is characterized by a PASI ≥125% of baseline or a new generalized pustular, erythrodermic, or more inflammatory psoriasis after stopping therapy.

    Time frame: Week 0 to Week 16; Placebo controlled phase

  11. Psoriasis Flare/Rebound

    Psoriasis flare is an AE and represents an atypical or unusual worsening of disease during treatment. It is defined as a sudden intensification of psoriasis requiring medical intervention or a diagnosis of new generalized erythrodermic, inflammatory, or pustular psoriasis. Rebound is an AE and is defined as a severe and sudden worsening of disease that occurs after treatment has been discontinued. This exacerbation is characterized by a PASI ≥125% of baseline or a new generalized pustular, erythrodermic, or more inflammatory psoriasis after stopping therapy. PASI ≥125% of baseline score at any visit after the last dose date for those who discontinued within the phase.

    Time frame: From the first dose of apremilast (either Week 0 or Week 16 for participants originally randomized to placebo or etanercept who were switched at Week 16) until 28 days after the last dose of apremilast.

08

Results

Posted Aug 4, 2015

Participant flow

The study was conducted at 65 study centers in 11 countries.

Placebo-controlled Phase (Weeks 0-16)
Participant flow — Placebo-controlled Phase (Weeks 0-16)
MilestonePlaceboApremilast Plus Placebo InjectionEtanercept Plus Placebo TabletPlacebo/ApremilastApremilast/ApremilastEtanercept/Apremilast
Started848383000
Safety population848383000
Completed757781000
Not completed962000
Withdrew: Adverse event221000
Withdrew: Lack of efficacy400000
Withdrew: Withdrawal by subject130000
Withdrew: Other211000
Apremilast Extension Phase (Weeks16-104)
Participant flow — Apremilast Extension Phase (Weeks16-104)
MilestonePlaceboApremilast Plus Placebo InjectionEtanercept Plus Placebo TabletPlacebo/ApremilastApremilast/ApremilastEtanercept/Apremilast
Started000737480
Safety population000737479
Completed000474150
Not completed000263330
Withdrew: Adverse event000343
Withdrew: Lack of efficacy0009108
Withdrew: Non-compliance with study drug000011
Withdrew: Withdrawal by subject0008511
Withdrew: Lost to follow-up0006136
Withdrew: Protocol violation000001

Outcome measures

PrimaryPercentage of Participants Who Achieved a 75% Improvement (Response) in the Psoriasis Area Severity Index (PASI-75) for the Comparison Between Apremilast and Placebo at Week 16 From Baseline

PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The PASI score was set to missing if any severity score or degree of involvement was missing.

Time frame:
Baseline to Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved a 75% Improvement (Response) in the Psoriasis Area Severity Index (PASI-75) for the Comparison Between Apremilast and Placebo at Week 16 From Baseline
Percentage of participantsPlaceboApremilast Plus Placebo Injection
Percentage of Participants Who Achieved a 75% Improvement (Response) in the Psoriasis Area Severity Index (PASI-75) for the Comparison Between Apremilast and Placebo at Week 16 From Baseline11.939.8
Statistical analysis
  • Placebo vs Apremilast Plus Placebo Injection · Cochran-Mantel-Haenszel · p = < 0.0001 (The two-sided p-value is from a CMH test stratified by the BMI at screening.) · Adjusted difference: 27.5 · 95% CI 14.9 to 40.1The confidence interval (CI) is weighted using CMH weights according to the number of participants in the two strata.
SecondaryPercentage of Participants Who Achieved a 75% Improvement (Response) in the Psoriasis Area and Severity Index (PASI) for the Comparison Between Etanercept 50mg SC QW and Placebo at Week 16

PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The PASI score was set to missing if any severity score or degree of involvement was missing.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a 75% Improvement (Response) in the Psoriasis Area and Severity Index (PASI) for the Comparison Between Etanercept 50mg SC QW and Placebo at Week 16
percentage of participantsPlaceboEtanercept 50mg Plus Placebo Tablet
Percentage of Participants Who Achieved a 75% Improvement (Response) in the Psoriasis Area and Severity Index (PASI) for the Comparison Between Etanercept 50mg SC QW and Placebo at Week 1611.948.2
Statistical analysis
  • Placebo vs Etanercept 50mg Plus Placebo Tablet · Cochran-Mantel-Haenszel · p = <0.0001 (The two-sided p-value is from a CMH test stratified by the BMI at screening.) · Adjusted difference: 35.9 · 95% CI 23.3 to 48.5The confidence interval (CI) is weighted using CMH weights according to the number of participants in the two strata.
SecondaryPercentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of Clear (0) or Almost Clear (1) With at Least 2 Points Reduction for Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16

The sPGA is an assessment by the Investigator of the overall disease severity at the time of evaluation. The sPGA is a 5-point scale ranging from 0 (clear) to 4 (severe), incorporating an assessment of the severity of the three primary signs of the disease: erythema, scaling and plaque elevation. When making the assessment of overall severity, the Investigator should factor in areas that have already been cleared (ie, have scores of 0) and not just evaluate remaining lesions for severity, ie, the severity of each sign is averaged across all areas of involvement, including cleared lesions. In the event of different severities across disease signs, the sign that is the predominant feature of the disease should be used to help determine the sPGA score.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of Clear (0) or Almost Clear (1) With at Least 2 Points Reduction for Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16
percentage of participantsPlaceboApremilast Plus Placebo InjectionEtanercept Plus Placebo Tablet
Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of Clear (0) or Almost Clear (1) With at Least 2 Points Reduction for Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 163.621.728.9
Statistical analysis
  • Placebo vs Apremilast Plus Placebo Injection · Cochran-Mantel-Haenszel · p = 0.0005 (The p-value is from a CMH test stratified by the BMI (Body Mass Index) at screening.) · Adjusted difference: 18.0 · 95% CI 8.4 to 27.7The Confidence Interval (CI) was weighted using CMH weights according to the number of participants in the two strata.
  • Placebo vs Etanercept Plus Placebo Tablet · Cochran-Mantel-Haenszel · p = <0.0001 (The p-value is from a CMH test stratified by the BMI (Body Mass Index) at screening.) · Adjusted difference: 25.2 · 95% CI 14.8 to 35.5The Confidence Interval (CI) was weighted using CMH weights according to the number of participants in the two strata.
SecondaryPercent Change From Baseline in the Affected Body Surface Area (BSA) for Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16

BSA is a measurement of involved skin. The overall BSA affected by psoriasis was estimated based on the palm area of the participant's hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total body surface area. BSA percent change from baseline was determined at each visit of the study, and is calculated as 100\*(post-baseline BSA - baseline BSA) / baseline BSA.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · percent change
Percent Change From Baseline in the Affected Body Surface Area (BSA) for Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16
percent changePlaceboApremilast Plus Placebo InjectionEtanercept Plus Placebo Tablets
Percent Change From Baseline in the Affected Body Surface Area (BSA) for Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16-16.3 (-23.71 to -8.81)-47.7 (-55.20 to -40.12)-56.1 (-63.63 to -48.59)
Statistical analysis
  • Placebo vs Apremilast Plus Placebo Injection · ANCOVA · p = <0.0001 · Difference in ls mean: -31.40 · 95% CI -43.33 to -19.46Based on ANCOVA model with treatment and screening BMI category as factors and baseline value as a covariate.
  • Placebo vs Etanercept Plus Placebo Tablets · ANCOVA · p = <0.0001 · Difference in ls mean: -39.85 · 95% CI -51.78 to -27.92Based on ANCOVA model with treatment and screening BMI category as factors and baseline value as a covariate.
SecondaryPercentage of Participants Who Achieved a 50% Improvement (Response) in the Psoriasis Area Severity Index (PASI-50) for Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16

PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 16. The PASI score was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The PASI score was set to missing if any severity score or degree of involvement was missing.

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a 50% Improvement (Response) in the Psoriasis Area Severity Index (PASI-50) for Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16
percentage of participantsPlaceboApremilast Plus Placebo InjectionEtanercept Plus Placebo Tablet
Percentage of Participants Who Achieved a 50% Improvement (Response) in the Psoriasis Area Severity Index (PASI-50) for Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 1633.362.783.1
Statistical analysis
  • Placebo vs Apremilast Plus Placebo Injection · Cochran-Mantel-Haenszel · p = 0.0002 (The two-sided p-value is from a CMH test stratified by the BMI at screening.) · Adjusted difference: 29.4 · 95% CI 14.9 to 43.9The confidence interval (CI) is weighted using CMH weights according to the number of participants in the two strata.
  • Placebo vs Etanercept Plus Placebo Tablet · Cochran-Mantel-Haenszel · p = <0.0001 (The two-sided p-value is from a CMH test stratified by the BMI at screening.) · Adjusted difference: 49.8 · 95% CI 36.9 to 62.7The confidence interval (CI) is weighted using CMH weights according to the number of participants in the two strata.
SecondaryChange From Baseline in Dermatology Life Quality Index (DLQI) Total Score In Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16

DLQI is a simple, compact, and practical questionnaire for use in a dermatology clinical setting to assess limitations related to the impact of skin disease. The instrument contains ten items dealing with the participant's skin. With the exception of Item Number 7, the participant responds on a four-point scale, ranging from "Very Much" (score 3) to "Not at All" or "Not relevant" (score 0). Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No, scores 3 or 0 respectively), and if "No," then the participant is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being "A lot," "A little," or "Not at all" (scores 2, 1, or 0 respectively). The DLQI total score is derived by summing all item scores, which has a possible range of 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score In Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16
units on a scalePlaceboApremilast 30mg Plus Placebo InjectionEtanercept 50mg Plus Placebo Tablet
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score In Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16-3.9 (-5.34 to -2.42)-8.4 (-9.84 to -6.88)-7.8 (-9.28 to -6.34)
Statistical analysis
  • Placebo vs Apremilast 30mg Plus Placebo Injection · ANCOVA · p = <0.0001 · Difference in ls mean: -4.48 · 95% CI -6.82 to -2.14Based on ANCOVA model with treatment and screening BMI category as factors and baseline value as a covariate.
  • Placebo vs Etanercept 50mg Plus Placebo Tablet · ANCOVA · p = 0.0004 · Difference in ls mean: -3.94 · 95% CI -6.27 to -1.60Based on ANCOVA model with treatment and screening BMI category as factors and baseline value as a covariate.
SecondaryChange From Baseline in the Mental Component Summary (MCS) Score of the Medical Outcome Study Short Form 36-item (SF-36) Health Survey Version 2.0 in Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16

The SF-36 is a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Scores from the 8 scales were transformed to the norm-based scores using weights from U.S. general population to have a mean of 50 and variance = 10, with higher scores indicating better health. From these 8 scale, two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS), both having the same mean of 50 and variance = 10 as noted for the individual scales for the U.S. general population, and with higher scores indicating better health. For MCS, change from baseline was calculated, where change = visit value - baseline value.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Mental Component Summary (MCS) Score of the Medical Outcome Study Short Form 36-item (SF-36) Health Survey Version 2.0 in Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16
units on a scalePlaceboApremilast Plus Placebo InjectionEtanercept Plus Placebo Tablets
Change From Baseline in the Mental Component Summary (MCS) Score of the Medical Outcome Study Short Form 36-item (SF-36) Health Survey Version 2.0 in Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 162.6 (0.72 to 4.43)3.5 (1.62 to 5.38)4.8 (2.92 to 6.67)
Statistical analysis
  • Placebo vs Apremilast Plus Placebo Injection · ANCOVA · p = 0.7112 · Difference in ls mean: 0.93 · 95% CI -2.05 to 3.90Based on ANCOVA model with treatment and screening BMI category as factors and baseline value as a covariate.
  • Placebo vs Etanercept Plus Placebo Tablets · ANCOVA · p = 0.1719 · Difference in ls mean: 2.22 · 95% CI -0.75 to 5.19Based on ANCOVA model with treatment and screening BMI category as factors and baseline value as a covariate.
SecondaryPercentage of Participants Who Achieved a Lattice System Physician's Global Assessment (LS-PGA) Score of Clear (0) or Almost Clear at Week 16 in Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16

The Lattice System Physician's Global Assessment is a global assessment performed by the investigator of psoriasis severity. Integrating ranges of BSA involvement with assessments of overall plaque severity (using a 4 point scale from none to marked for the signs of plaque elevation, erythema and scale), the LS-PGA produces an overall assessment of psoriasis severity on an 8-point scale, ranging from clear to very severe. To determine the final score, the lattice portion is governed by the BSA and among the plaque qualities, weights plaque elevation as most important, erythema next, and scale least.

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Lattice System Physician's Global Assessment (LS-PGA) Score of Clear (0) or Almost Clear at Week 16 in Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16
percentage of participantsPlaceboApremilast Plus Placebo InjectionEtanercept Plus Placebo Tablets
Percentage of Participants Who Achieved a Lattice System Physician's Global Assessment (LS-PGA) Score of Clear (0) or Almost Clear at Week 16 in Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 166.024.122.9
Statistical analysis
  • Placebo vs Apremilast Plus Placebo Injection · Cochran-Mantel-Haenszel · p = 0.0011 (The two-sided p-value is from a CMH test stratified by the BMI at screening.) · Adjusted difference: 18.1 · 95% CI 7.6 to 28.6The confidence interval (CI) is weighted using CMH weights according to the number of participants in the two strata.
  • Placebo vs Etanercept Plus Placebo Tablets · Cochran-Mantel-Haenszel · p = 0.0021 (The two-sided p-value is from a CMH test stratified by the BMI at screening.) · Adjusted difference: 16.7 · 95% CI 6.5 to 26.9The confidence interval (CI) is weighted using CMH weights according to the number of participants in the two strata.
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAE) During the Placebo-Controlled Phase

A TEAE is an AE with a start date on or after the date of the first dose of study drug and no later than 28 days after the last dose of study drug for participants who discontinued early. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen during the study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the patient's health, including laboratory test values, regardless of etiology. Any worsening (ie, clinically significant adverse change in frequency or intensity of a preexisting condition) should be considered an AE. A serious AE (SAE) is any untoward AE that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize or may require intervention to prevent one of the outcomes above.

Time frame:
Week 0 to Week 16; mean duration of exposure was 14.90 weeks for placebo group, 15.13 weeks for apremilast group and 15.87 weeks for Etanercept group
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Placebo-Controlled Phase
participantsPlaceboApremilast Plus Placebo InjectionEtanercept Plus Placebo Tablets
Any TEAE455944
Any Drug-related TEAE172721
Any Severe TEAE233
Any Serious TEAE032
Any Serious Drug-related TEAE021
Any TEAE Leading to Drug Interruption193
Any TEAE Leading to Drug Withdrawal232
Any TEAE Leading to Death000
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAE) During the Apremilast-exposure Period

A TEAE in the apremilast-exposure phase is an AE with a start date on or after the date of the first dose of study drug and no later than 28 days after the last dose of study drug. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen during the study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE. A serious AE (SAE) is any untoward AE that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize or may require intervention to prevent one of the outcomes listed above.

Time frame:
From the first dose of apremilast (either Week 0 for participants originally randomized to apremilast or Week 16 for those originally randomized to placebo or etanercept who were switched to apremilast at week 16) until 28 days after last apremilast dose
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Apremilast-exposure Period
participantsPlacebo/ApremilastApremilast/ApremilastEtanercept/Apremilast
Any TEAE457154
Any Drug-related TEAE233615
Any Severe TEAE477
Any Serious TEAE564
Any Serious Drug-related TEAE221
Any TEAE Leading to Drug Interruption8137
Any TEAE Leading to Drug Withdrawal372
Any TEAE Leading to Death000
SecondaryPsoriasis Flare/Rebound

Psoriasis flare is an AE and represents an atypical or unusual worsening of disease during treatment. It is defined as a sudden intensification of psoriasis requiring medical intervention or a diagnosis of new generalized erythrodermic, inflammatory, or pustular psoriasis. Rebound is an AE and is defined as a severe and sudden worsening of disease that occurs after treatment has been discontinued. This exacerbation is characterized by a PASI ≥125% of baseline or a new generalized pustular, erythrodermic, or more inflammatory psoriasis after stopping therapy.

Time frame:
Week 0 to Week 16; Placebo controlled phase
Reported as:
Number · participants
Psoriasis Flare/Rebound
participantsPlaceboApremilast Plus Placebo InjectionEtanercept Plus Placebo Tablets
Any psoriasis flare captured as a TEAE310
Any psoriasis rebound captured as a TEAE000
Those with PASI ≥125% baseline score and D/C APR100
SecondaryPsoriasis Flare/Rebound

Psoriasis flare is an AE and represents an atypical or unusual worsening of disease during treatment. It is defined as a sudden intensification of psoriasis requiring medical intervention or a diagnosis of new generalized erythrodermic, inflammatory, or pustular psoriasis. Rebound is an AE and is defined as a severe and sudden worsening of disease that occurs after treatment has been discontinued. This exacerbation is characterized by a PASI ≥125% of baseline or a new generalized pustular, erythrodermic, or more inflammatory psoriasis after stopping therapy. PASI ≥125% of baseline score at any visit after the last dose date for those who discontinued within the phase.

Time frame:
From the first dose of apremilast (either Week 0 or Week 16 for participants originally randomized to placebo or etanercept who were switched at Week 16) until 28 days after the last dose of apremilast.
Reported as:
Number · participants
Psoriasis Flare/Rebound
participantsPlacebo/ApremilastApremilast/ApremilastEtanercept/Apremilast
Any psoriasis flare captured as a TEAE140
Any psoriasis rebound captured as a TEAE127
Those with PASI ≥125% baseline score and D/C APR001

Adverse events

Collected over Adverse events are reported for the 16-week placebo-controlled period and up to week 104 during the apremilast exposure period for all participants who were randomized or switched to apremilast at any time during the course of the study.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Week 0-16)—0/84 (0%)25/84 (29.8%)
Apremilast Plus Placebo Injection (Week 0-16)—3/83 (3.6%)41/83 (49.4%)
Etanercept Plus Placebo Tablets (Week 0-16)—2/83 (2.4%)27/83 (32.5%)
Placebo/APR 30mg (Apremilast Exposure Phase) Weeks 16-104—5/73 (6.8%)30/73 (41.1%)
APR/APR 30 mg (Apremilast Exposure Phase) Weeks 0-104—6/83 (7.2%)52/83 (62.7%)
Etanercept/APR 30mg (Apremilast Exposure Phase) Weeks 16-104—4/79 (5.1%)32/79 (40.5%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventPlacebo (Week 0-16)Apremilast Plus Placebo Injection (Week 0-16)Etanercept Plus Placebo Tablets (Week 0-16)Placebo/APR 30mg (Apremilast Exposure Phase) Weeks 16-104APR/APR 30 mg (Apremilast Exposure Phase) Weeks 0-104Etanercept/APR 30mg (Apremilast Exposure Phase) Weeks 16-104
Non-cardiac chest painGeneral disorders0/840/830/831/730/830/79
CholelithiasisHepatobiliary disorders0/840/830/831/730/830/79
Anogenital wartsInfections and infestations0/840/830/831/730/830/79
Traumatic intracranial haemorrhageInjury, poisoning and procedural complications0/840/830/831/730/830/79
PneumocephalusNervous system disorders0/840/830/831/730/830/79
SyncopeNervous system disorders0/840/830/831/730/830/79
Psychotic disorderPsychiatric disorders0/840/830/831/730/830/79
Suicidal ideationPsychiatric disorders0/840/830/831/730/830/79
Deafness unilateralEar and labyrinth disorders0/840/830/830/730/831/79
Abscess intestinalInfections and infestations0/840/830/830/730/831/79
Most frequent other events
Showing 10 of 18
Most frequent other events
EventPlacebo (Week 0-16)Apremilast Plus Placebo Injection (Week 0-16)Etanercept Plus Placebo Tablets (Week 0-16)Placebo/APR 30mg (Apremilast Exposure Phase) Weeks 16-104APR/APR 30 mg (Apremilast Exposure Phase) Weeks 0-104Etanercept/APR 30mg (Apremilast Exposure Phase) Weeks 16-104
DiarrhoeaGastrointestinal disorders3/849/831/8313/7312/836/79
NauseaGastrointestinal disorders1/849/834/835/7312/835/79
HeadacheNervous system disorders3/8411/835/835/7312/833/79
Upper Respiratory Tract InfectionInfections and infestations2/846/832/835/739/831/79
NasopharyngitisInfections and infestations8/844/838/834/735/835/79
Rebound psoriasisSkin and subcutaneous tissue disorders0/840/830/831/732/837/79
VomitingGastrointestinal disorders2/844/832/833/736/832/79
RhinitisInfections and infestations1/844/834/831/736/832/79
ArthralgiaMusculoskeletal and connective tissue disorders2/843/833/834/736/833/79
Psoriatic arthropathyMusculoskeletal and connective tissue disorders2/844/830/833/736/831/79

Baseline characteristics

Randomized population includes all randomized participants.

Age, Continuous
Age, Continuous(years)PlaceboApremilast Plus Placebo InjectionEtanercept Plus Placebo TabletTotal
Mean43.4 ± 14.9146.0 ± 13.5947.0 ± 14.0745.4 ± 14.23
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboApremilast Plus Placebo InjectionEtanercept Plus Placebo TabletTotal
Female25343493
Male594949157
09

Study locations

82 sites
  • Arizona Research Center
    Phoenix, Arizona 85023, United States
  • Bakersfield Dermatology and Skin Cancer Medical Group
    Bakersfield, California 93309, United States
  • University of California Irvine-Department of Dermatology
    Irvine, California 92697, United States
  • University of California San Diego Medical Center
    San Diego, California 92122, United States
  • Horizons Clinical Research
    Denver, Colorado 80220, United States
  • George Washington University
    Washington, District of Columbia 20037, United States
  • Florida Center for Dermatology, PA
    Jacksonville, Florida 32204, United States
  • Florida Academic Dermatology Center
    Miami, Florida 33136, United States
  • International Dermatology Research
    Miami, Florida 33144, United States
  • Renstar Medical Research
    Ocala, Florida 34471, United States
  • Atlanta Dermatology, Vein and Research Center, PC
    Alpharetta, Georgia 30022, United States
  • NorthShore University HealthSystem
    Skokie, Illinois 60077, United States
  • Southern Illinois University School of Medicine
    Springfield, Illinois 62702, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46256, United States
  • Dermatology and Advanced Aesthetics
    Lake Charles, Louisiana 70605, United States
  • Lawrence Green, MD, LLC
    Rockville, Maryland 20850, United States
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Robert Wood Johnson Medical School
    Somerset, New Jersey 08873, United States
  • Forest Hills Dermatology Group
    Forest Hills, New York 11375, United States
  • NYU Department of Dermatology
    New York, New York 10016, United States
  • University of North Carolina
    Chapel Hill, North Carolina 27516, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27104, United States
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • Ohio State University Medical Center
    Columbus, Ohio 43230, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • Tennesse Clinical Research Center
    Nashville, Tennessee 37215, United States
  • Teckton Research
    Austin, Texas 78745, United States
  • The Education and Research Foundation
    Lynchburg, Virginia 24501, United States
  • Virginia Clinical Research Inc
    Norfolk, Virginia 23507, United States
  • Dermatology Associates of Seattle
    Seattle, Washington 98101, United States
  • The Skin Centre
    Benowa, Queensland 4217, Australia
  • Sinclair Dermatology
    East Melbourne, Victoria 3002, Australia
  • Fremantle Dermatology
    Fremantle, Western Australia 6160, Australia
  • Gairdner Hospital
    Victoria Park, 6100, Australia
  • Rheumatology unit Ward 5C Queen Elizabeth Hospital
    Woodville, 5011, Australia
  • Veracity Clinical Research
    Woolloongabba, 4102, Australia
  • Cliniques Universitaires St-Luc
    Brussels, 1200, Belgium
  • University Hospital Ghent
    Ghent, 9000, Belgium
  • University Hospital of Liege CHU Liege
    Liege, 4000, Belgium
  • Eastern Canada Cutaneous Research Associates Ltd
    Halifax, Nova Scotia B3H 1Z4, Canada
  • Skin Center for Dermatology
    Peterborough, Ontario K9J 5K2, Canada
  • K. Papp Clinical Research Inc.
    Waterloo, Ontario N2J 1C4, Canada
  • Siena Medical Research
    Montreal, Quebec H3Z 2S6, Canada
  • Q & T Research Sherbrooke Inc.
    Sherbrooke, Quebec J1H 4J6, Canada
  • Dorothea, Kožní a korektivne dermatologické pracovište
    Chomutov, 430 04, Czechia
  • Dermamedica
    Nachod, 54701, Czechia
  • Východoceské dermatologické centrum Homea s.r.o.
    Pardubice, 530 02, Czechia
  • Krajská nemocnice Pardubice, Kožní oddelení
    Pardubice, 532 03, Czechia
  • Dermatovenerologicka ambulance
    Svitavy, 568 02, Czechia
  • Koznia zilni ambulance
    Ústí nad Labem, 400 10, Czechia
  • South Estonian Hospital Ltd
    Meegomäe Village, Võru County, 65526, Estonia
  • Dermatology Clinic of Tartu University Hospital
    Tartu, 50417, Estonia
  • Psoriasis Study Center
    Berlin, 10117, Germany
  • Dermatologische Praxis
    Berlin, 10827, Germany
  • Klinische Forschung Berlin - Buch GmbH
    Berlin, 13125, Germany
  • University Hospital Carl Gustav Carus
    Dresden, 1307, Germany
  • Hautklinik Universitatsklinikum Erlangen
    Erlangen, 91054, Germany
  • University Hospital Frankfurt
    Frankfurt, 60590, Germany
  • SCIderm GmbH
    Hamburg, 20354, Germany
  • Institute for Health Services Research in Dermatology and Nursing - IVDP, University Medical Center
    Hamburg, D-20246, Germany
  • Universitatsklinikum Heidelberg
    Heidelberg, 69115, Germany
  • UniversitatsKlinikum Leipzig A.o.R.
    Leipzig, 4103, Germany
  • Comprehensive Center of Inflammatory Medicine (CCIM) University Medical Center Schleswig-Holstein
    Lübeck, 23538, Germany
  • Gemeinschaftspraxis Mahlow
    Mahlow, 15831, Germany
  • University Hospital Munster
    Münster, 48143, Germany
  • Praxis fr Dermatologie und Venerologie
    Wuppertal, 42275, Germany
  • Tolna Megyei Balassa Janos Korhaz
    Szekszárd, 7100, Hungary
  • Allergo-Derm Bakos Kft.
    Szolnok, 5000, Hungary
  • LTD M & M centrs
    Adazi, 2164, Latvia
  • Arija's Ancane's Family Doctor Private Practice
    Baldone, 2125, Latvia
  • Riga 1st Hospital Skin and Sexually Transmitted Diseases Clinical Centre
    Riga, 1001, Latvia
  • Adoria Ltd
    Riga, 1011, Latvia
  • Family Doctor's Indra's Kenina's Practice
    Riga, 1011, Latvia
  • Health Center of Talsi Ltd
    Talsi, 3201, Latvia
  • Academic Medical Center
    Amsterdam, 1105 AZ, Netherlands
  • Radboud University Medical Centre
    Nijmegen, 6500HB, Netherlands
  • University Hospital of Wales
    Cardiff, CF14 4XN, United Kingdom
  • Leeds Teaching Hospitals Trust
    Leeds, LS7 4SA, United Kingdom
  • Whipps Cross University Hospital
    London, E11 1NR, United Kingdom
  • St Helier Hospital
    London, SM5 1AA, United Kingdom
  • George Eliot Hospital
    Nuneaton, CV10 7DJ, United Kingdom
10

References and documents

Publications

  • Reich K, Mrowietz U, Menter A, Griffiths CEM, Bagel J, Strober B, Nunez Gomez N, Shi R, Guerette B, Lebwohl M. Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis. J Eur Acad Dermatol Venereol. 2021 Dec;35(12):2409-2414. doi: 10.1111/jdv.17520. Epub 2021 Aug 23. PubMed 34255891 ↗
  • Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, Day RM, Goncalves J, Shah K, Piguet V, Soung J. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venereol. 2017 Mar;31(3):507-517. doi: 10.1111/jdv.14015. Epub 2016 Dec 19. PubMed 27768242 ↗

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2012 to primary completion in Jul 2014, 21 months.

Results were first posted in Aug 2015, 1 year 1 month after primary completion.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 21 months is below that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2012
First posted
Sep 21, 2012
StartActual
Oct 1, 2012
Primary completionActual
Jul 3, 2014
CompletionActual
Apr 4, 2016
Results first posted
Aug 4, 2015
Last update
Mar 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01690299
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Sep 21, 2012
Start date
Oct 1, 2012
Primary completion
Jul 3, 2014
Completion
Apr 4, 2016
Results posted
Aug 4, 2015
Last update
Mar 15, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Apremilast · Etanercept

Start the discussion